Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Puma Biotechnology's profit margin for the twelve months ending Jun 30, 2026 was 11.6%. For fiscal 2025 it was 13.6%, against 13.1% the year before. The highest annual figure on record is 13.6% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.6% | +0.5 |
| FY2024 | Dec 31, 2024 | 13.1% | +4.0 |
| FY2023 | Dec 31, 2023 | 9.2% | +9.2 |
| FY2022 | Dec 31, 2022 | 0.0% | +11.5 |
| FY2021 | Dec 31, 2021 | -11.5% | +15.1 |
| FY2020 | Dec 31, 2020 | -26.7% | +1.1 |
| FY2019 | Dec 31, 2019 | -27.8% | +17.5 |
| FY2018 | Dec 31, 2018 | -45.3% | +1009.3 |
| FY2017 | Dec 31, 2017 | -1054.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 14.5% | +3.3 |
| Q1 FY2026 | Mar 31, 2026 | -8.4% | −14.8 |
| Q4 FY2025 | Dec 31, 2025 | 17.8% | −14.9 |
| Q3 FY2025 | Sep 30, 2025 | 16.2% | −9.0 |
| Q2 FY2025 | Jun 30, 2025 | 11.2% | +20.8 |
| Q1 FY2025 | Mar 31, 2025 | 6.5% | +17.5 |
| Q4 FY2024 | Dec 31, 2024 | 32.7% | +15.7 |
| Q3 FY2024 | Sep 30, 2024 | 25.2% | +14.9 |
| Q2 FY2024 | Jun 30, 2024 | -9.6% | −13.5 |
| Q1 FY2024 | Mar 31, 2024 | -11.0% | −13.7 |
| Q4 FY2023 | Dec 31, 2023 | 17.0% | +25.5 |
| Q3 FY2023 | Sep 30, 2023 | 10.3% | +11.0 |
| Q2 FY2023 | Jun 30, 2023 | 3.9% | −11.8 |
| Q1 FY2023 | Mar 31, 2023 | 2.7% | +10.1 |
| Q4 FY2022 | Dec 31, 2022 | -8.5% | −16.2 |
| Q3 FY2022 | Sep 30, 2022 | -0.6% | +96.0 |
| Q2 FY2022 | Jun 30, 2022 | 15.7% | +25.3 |
| Q1 FY2022 | Mar 31, 2022 | -7.4% | −24.3 |
| Q4 FY2021 | Dec 31, 2021 | 7.6% | +36.2 |
| Q3 FY2021 | Sep 30, 2021 | -96.6% | −34.6 |
| Q2 FY2021 | Jun 30, 2021 | -9.6% | −14.4 |
| Q1 FY2021 | Mar 31, 2021 | 16.8% | +49.9 |
| Q4 FY2020 | Dec 31, 2020 | -28.5% | −10.7 |
| Q3 FY2020 | Sep 30, 2020 | -62.0% | −32.0 |
| Q2 FY2020 | Jun 30, 2020 | 4.8% | +74.2 |
| Q1 FY2020 | Mar 31, 2020 | -33.1% | −22.9 |
| Q4 FY2019 | Dec 31, 2019 | -17.8% | +25.4 |
| Q3 FY2019 | Sep 30, 2019 | -30.0% | −7.3 |
| Q2 FY2019 | Jun 30, 2019 | -69.4% | +17.9 |
| Q1 FY2019 | Mar 31, 2019 | -10.2% | +26.4 |
| Q4 FY2018 | Dec 31, 2018 | -43.2% | +253.4 |
| Q3 FY2018 | Sep 30, 2018 | -22.7% | +1247.4 |
| Q2 FY2018 | Jun 30, 2018 | -87.3% | – |
| Q1 FY2018 | Mar 31, 2018 | -36.6% | – |
| Q4 FY2017 | Dec 31, 2017 | -296.5% | – |
| Q3 FY2017 | Sep 30, 2017 | -1270.0% | – |
See a number that looks wrong?